Early screening for preeclampsia

Abstract

Preeclampsia, which affects about 3 to 5% of pregnant women, is the most frequent medical complication in pregnancy and the most important cause of maternal and perinatal morbidity and mortality. During the past three decades, numerous clinical, biophysical, and biochemical screening tests have been proposed for the early detection of preeclampsia. Literature shows large discrepancies in the sensitivity and predictive value of several of these tests. No single screening test used for preeclampsia prediction has gained widespread acceptance into clinical practice. Instead, its value seems to be in increasing the predictive value of panels of tests, which include other clinical measurements. The aim of this review was to examine the combination of maternal risk factors, mean arterial blood pressure, and uterine artery Doppler, together with biomarkers in the preeclampsia prediction.

Keywords

Pre-eclampsia/diagnosis
Risk factors
Uterine artery/ultrasonography
Biological biomarkers

Palavras-chave

Pré-eclâmpsia/diagnóstico
Fatores de risco
Artéria uterina/ultrassonografia
Marcadores biológicos
Introduction

Preeclampsia (PE) is one of the hypertensive pregnancy disorders, which affects from 3 to 5% of pregnant women. It is the most important cause of maternal morbidity and perinatal mortality. On a global scale, PE is responsible for approximately 50,000 maternal deaths annually. In addition, PE frequently coexists with intrauterine growth restriction (IUGR, also called fetal growth restriction), placental abruption, and the need for iatrogenic preterm delivery, which are additional major causes of adverse outcomes.

PE is developed after 20 weeks of gestation and is characterized by hypertension and proteinuria. However, the pathophysiology of PE remains incompletely elucidated. Circulating factors are postulated to be produced by the placenta as a result of oxidative stress. This may cause excessive systemic inflammatory response and generalized maternal endothelial dysfunction, contributing to the maternal clinical features of PE. Shallow placentation is associated with abnormal invasion of cytrophoblasts, leading to incomplete remodeling of maternal uterine spiral arterioles, which supply blood to the developing placenta. The ensuing hypoxic stress in the placenta is associated with the release of endothelial damaging factors into the maternal circulation.

PE can be classified into early- and late-onset, and it is widely accepted that these subtypes of PE represent different forms of the disease. Early-onset PE is commonly associated with IUGR, abnormal uterine, and umbilical artery Doppler waveforms, and adverse maternal as well as neonatal outcomes. In contrast, late-onset PE is mostly associated with mild maternal disease and low rate of fetal involvement; the perinatal outcomes are usually favorable.

A major retrospective study showed that current standards of prenatal care are not effective for identifying relatively common obstetric problems, such as PE in low-risk populations. Furthermore, a randomized multicenter study concluded that regular obstetric consultations conducted in a tertiary centre do not improve the antenatal detection of PE, compared with primary care.

During the past three decades, numerous clinical, biophysical, and biochemical tests have been proposed for early detection of PE. These tests can require either noninvasive or invasive procedures, or a combination of both, to obtain the sample or measurement. Some tests have been studied extensively, whilst others are still at the level of laboratory research or under pre-clinical trials. Literature shows large discrepancies in the sensitivity and predictive value of several of these tests. It is a contributing factor to the lack of widespread adoption of these tests into clinical practice.

Early detection of PE would allow for planning the appropriate monitoring and for clinical management, following the early identification of disease complications. Although trials of prophylactic intervention for PE from mid-gestation have not been efficacious, it has been suggested that a very early prediction of PE in gestation may make early prophylactic strategies more effective.

Reliable antenatal identification of PE is crucial to cost-effective allocation of monitoring resources and to use possible preventative treatment with the hope of improving maternal and perinatal outcomes. The literature is difficult to interpret and this prevents the implementation of good clinical management practices for the several clinical scenarios of PE. The variation in research design for determining the test accuracy for the prediction of PE, the scatter of this research across many databases and languages, and the dearth of clear, collated up-to-date summaries of the relevant literature, contribute to the uncertainty about the best screening and monitoring strategies. A logical approach to obtain an ideal predictive test for PE is to utilize a combination of several potential predictors, which reflect different aspects of the disease.

Maternal factors

Maternal history including ethnic origin, parity, body mass index (BMI), and personal or family history of PE are well-known risk factors for PE. Among women considered as high-risk, approximately 25% will develop PE compared with 5% in the general population.

The National Institute of Clinical Excellence (NICE) in the United Kingdom (UK) recommends a screening strategy based on maternal history and on other risk factors. Unfortunately, it categorizes more than 60% of pregnant women as high-risk and predicts less than 30% of those destined to develop PE, at a false-positive rate of 10%. Poon et al. showed in a study on a large population that certain risk factors significantly predicted early- and late-onset PE with different detection rates of 37 and 29%, respectively, for a 5% false-positive rate. Different subsets of factors were better at predicting early-onset PE (previous history of PE, black ethnicity, pre-existing hypertension, and previous use of ovulation inducers) than the late one (maternal or family history of PE, black ethnicity, BMI, and maternal age). Pre-existing maternal subclinical endothelial dysfunction is likely to make a woman more vulnerable to poor placentation and more sensitive to the consequences of placental dysfunction.

The SCOPE Group developed a predictive model for PE based on clinical risk factors for nulliparous women.
Using that approach, 9% of nulliparous women would be referred to a specialist care, of whom 21% would develop PE. The authors concluded that the ability to predict PE in healthy nulliparous women using clinical phenotype is modest and requires external validation in other populations. Unfortunately, screening for PE using maternal history alone is an unreliable method. This is especially true in primigravid women, the very population where the incidence of PE is the highest. Since the development of PE is thought to include abnormal placentation and its vascular supply, it is logical to follow the evaluation of uterine artery blood flow resistance. Some recent publications showed that a more effective approach is the one that combines maternal history with measurement of blood pressure, uterine artery Doppler, and serum biomarkers.

**Mean arterial blood pressure**

Very small changes in the blood pressure were found to be a marker of the risk of developing PE. Women who subsequently develop PE have higher systolic blood pressure and mean arterial blood pressure (MAP) readings before the onset of clinical disease where MAP is twice the diastolic plus the systolic blood pressure, divided by three.

Changes in blood pressure are most likely a proxy for increased maternal vascular susceptibility to PE, or they are a marker for underlying and undiagnosed hypertension. Accurate measurement of blood pressure using a validated automatic monitor is particularly important when attempting to identify early signs of PE. As a means of prediction, the MAP, whether measured in the first or second trimester, is suggested to be a better predictor than the systolic and diastolic blood pressure or an increase in blood pressure. Cnossen et al. conducted a systematic review and they showed that the MAP was a better predictor for PE than an increase in either the systolic or diastolic blood pressure. Second trimester MAP of 90 mmHg or above showed a positive likelihood ratio of 3.5 (95% CI = 2.5) and a negative likelihood ratio of 0.46 (95% CI = 0.16-0.75). In a prospective cohort study, the utility of MAP was assessed in 104 patients, who subsequently developed PE, and 4,418 patients unaffected by hypertensive disease and with normal birth-weight infants. Combining MAP with prior risk factors, the observed detection rate PE was 62%.

Maternal MAP is an easy, cost-effective, and noninvasive test that can be performed in all women at their first routine antenatal visit. MAP can readily be combined with uterine artery Doppler studies and biomarkers.

### Ultrasound

**Uterine artery Doppler**

Poor placentation with deficient remodeling of the spiral arteries has been associated with subsequent development of the early-onset forms of PE, IUGR, and other associated complications. In these abnormal pregnancies, the uteroplacental circulation remains in a state of high resistance, which can be measured noninvasively by uterine artery Doppler ultrasound. The impedance is increased in early PE and IUGR and predicts the onset of the clinical symptoms by several weeks.

A number of studies examined the effectiveness of uterine artery Doppler in predicting the complications associated with impaired placentation. Most studies used uterine artery Doppler measured in the second trimester, but there is an increasing number of studies showing the effectiveness of first trimester uterine Doppler measurements in the prediction of PE and IUGR. Early reports used subjective qualitative assessment evaluating the presence of a diastolic notch. However, in the last ten years, the use of continuous variables has achieved widespread acceptance as they provide more objective measurements to quantify the vascular impedance. Specifically, the mean pulsatility index (PI) has been studied as an objective measurement, and normal ranges from 11 to 41 weeks have been published.

A feature of uterine artery screening is that the detection rates are better for the pre-term and/or early form of PE than for severe or mild PE. Second-trimester uterine artery Doppler studies showed detection rates of 70 to 80% for pre-term PE, while the detection rates are 50 to 40% for PE at any gestational age, with false-positive rates between 5 and 7%. In Brazil, Costa et al. when studying second trimester uterine artery Doppler in a low-risk population, showed high sensitivity for prediction of PE, however with only a 29% positive predictive value.

First trimester screening shows a similar trend, although overall detection rates are lower than second trimester screening. Around 40% of women who subsequently develop PE requiring delivery at less than 37 weeks gestation will be correctly classified, with a false-positive rate of 5%.

The use of uterine artery Doppler as a screening tool for PE and other pregnancy complications, such as IUGR, remains controversial. Criticism has tended to focus on the low-positive predictive values for term disease reported in clinical trials in low-risk populations. However, when attention is focused on early-onset PE, which causes the highest burden of perinatal morbidity and mortality, the evaluation of uterine artery Doppler performance suggests it is an important predictor. The search continues for a combination of tests that could work better than, or in...
association with, uterine artery Doppler to maintain the high sensitivity, but that improve specificity\(^1\).

### Placental volume and 3D power Doppler

Placental maldevelopment plays a pivotal role in the pathogenesis of PE. Three-dimensional (3D) ultrasound has the potential to provide improved visualization of the fetal anatomy compared with conventional 2D ultrasound imaging. Consequently, the introduction of 3D ultrasound would facilitate the novel assessment of the placenta, such as surface-rendering imaging and volume measurement. With the recent advances in 3D Power Doppler ultrasound, as well as quantitative 3D Power Doppler histogram analysis, quantitative and qualitative assessments of the vascularization and blood flow of the placenta have become feasible\(^2\). 3D sonographic placental volume measurements using multiplanar Virtual Organ Computer-aid Analysis (VOCAL) and Extended Imaging VOCAL (XI VOCAL) have been reported. Studies on the prediction of adverse pregnancy outcomes, including IUGR and PE using placental volume measurement in the first trimester of pregnancy, have shown inconsistent results\(^3\).

3D power Doppler ultrasound can depict internal placental vessel characteristics such as density of vessels, branching, caliber changes, and tortuosity\(^4\). Several small studies have suggested that parameters derived from 3D Power Doppler evaluation of the placenta in the first trimester can predict adverse pregnancy outcomes, including PE and IUGR. While the findings from these studies are promising, the methodologies used and the definitions of abnormal indices have varied\(^5\). In a recent prospective nonintervention study of 277 women at 10 to 13 weeks, the 24 who later presented PE had significantly reduced indices of vascularization and blood flow\(^6\). It remains to be seen if first trimester placental volume using 3D Power Doppler is an independent marker of PE compared with uterine artery Doppler PI.

### Biomarkers

Biochemical markers of PE are circulating factors, the measurement of which could potentially be used in the diagnosis or prediction of PE. Some markers are products of trophoblast cells or of the adjacent decidua and they reflect placental dysfunction, which is an important aspect of the PE pathogenesis. Other biomarkers include inflammatory and metabolic markers arising from systemic responses of maternal systems to abnormal pregnancy. An increasing number of biomarkers in the maternal serum display altered concentrations during the first trimester of pregnancy\(^7\).

In this review, we described known biomarkers of PE based on their source. The first group of biomarkers are exclusively placental in origin, such as PP13. This group can be further subdivided into those that are expressed in the placental villous trophoblast or in the extravillous one. The second group are biomarkers exclusively of maternal origin like P-selectin. The third group of biomarkers is expressed by both maternal and fetal tissues, such as s-Flt and PIGF.

### Biomarkers from the placenta

#### Pregnancy-associated placental protein A

Pregnancy-associated placental protein A (PAPP-A) is a large and highly glycosylated protein, which is produced by the developing trophoblast. PAPP-A modulates the activity of insulin-like growth factors by cleaving insulin-like growth factor binding proteins\(^8\). It is proposed to play a role in implantation\(^9\) and is used as a biomarker for Down’s syndrome. In chromosomally normal pregnancies, there is evidence that low maternal serum PAPP-A is associated with an increased risk of subsequently developing PE. However, measurement of PAPP-A is not an effective stand alone screening tool for PE, because less than 20% of the affected cases present serum levels below the fifth centile\(^10\).

#### Placental protein 13

Placental protein 13 (PP13) is a member of the galectin family and is a 32-kDa dimer protein, which is highly expressed in placenta, and specifically by the syncytiotrophoblast\(^11\). Several studies since 2004 have demonstrated that low concentrations of maternal serum PP13 in the first trimester predict PE\(^12\). Decreased mRNA for PP13 was also found in the first trimester\(^13\). In general, low PP13 in the first trimester seems to be a better predictor of early onset and severe PE than mild PE at term\(^14\).

#### Cystatin C

Maternal serum cystatin C is another independent marker of PE\(^1\). It is an inhibitor of cysteine proteases, which are thought to play an important role in matrix degradation during normal trophoblast invasion. Cystatin C is reportedly increased in PE and it is also elevated in the first trimester in women destined to have PE, compared with those who will have a normal pregnancy\(^15\).

#### Fetal cells

Several independent studies have shown that PE is associated with an underlying placental lesion that
facilitates the increased trafficking of fetal cells and the release of cell-free fetal DNA. These studies have also shown that this placental defect occurs early in pregnancy, long before the onset of any clinical symptoms. Although advances have been made in the enrichment and isolation of fetal cells for analysis, a large multicentre analysis by the National Institutes of Health (NIH) revealed that the sensitivity and specificity of cell-based methods were not satisfactory for aneuploidy detection.

**Cell free fetal RNA and DNA**

Cell free fetal DNA (cffDNA) detection has been widely developed for use in noninvasive prenatal diagnosis. Most of the studies so far have demonstrated a significant difference in cffDNA levels in second trimester samples of patients that subsequently develop PE versus controls. Studying placental and fetal gene expression by analyzing circulating fetal mRNA has recently shown promising results. Fetal RNA molecules in maternal plasma are associated with subcellular particles, including apoptotic bodies and syncytiotrophoblast microparticles. Zhong et al. and Purwosunu et al. have reported a parallel assessment of cffDNA and placental specific mRNA (i.e. corticotropin releasing hormone mRNA) in the second trimester, and they revealed that both were increased in early onset PE.

**Inhibin A and activin A**

Inhibin A and activin A are glycoprotein hormones and members of the transforming growth factor (TGF)-β family. The placenta is the primary source of these circulating proteins during pregnancy and their concentrations increase in the third trimester of uncomplicated pregnancies. In a study, by Muttukrishna et al., increased serum inhibin A and activin A from second trimester was a poor predictor of PE, with a predictive sensitivity from 16 to 59%. However, early-onset disease was better predicted than the term-onset one. Also, Sibai et al. found that elevated second trimester serum inhibin A had a poor sensitivity in predicting PE in a high-risk group of women.

**Angiogenic factors**

Angiogenesis requires the complex interplay between the pro-angiogenic factors, vascular endothelial growth factor (VEGF) and placental growth factor (PIGF), with their cognate receptors VEGF receptor-1 (VEGFR-1, which is alternatively called FMS-like tyrosine kinase (flt)-1) and VEGFR-2. Interestingly, the placenta is a rich source of these factors, and several of these angiogenic factors have been shown to be key components in regulating trophoblast cell survival and function. A cleaved form of soluble-Flt-1 has been reported to increase during third trimester in women who will develop PE within five weeks and at the time of the disease. The mRNA encoding PIGF is produced in large amounts by villous and extravillous cytotrophoblasts and syncytiotrophoblasts. PE is associated with decreased serum PIGF in the early onset. An additional angiogenic factor, soluble endoglin (sENG) was also observed to increase in PE. Thus, alterations in sFlt, PIGF and sENG are more pronounced in early onset PE compared with late onset PE. A review of the literature for angiogenic markers reveals that they are mostly not specific for PE, since similar changes in angiogenic marker profiles are observed in cases of fetal growth restriction not associated with PE. This is particularly the case with sENG.

**Molecules of maternal origin**

Pentraxin 3 (PTX3), an inflammatory molecule that belongs to PTX family such as C-reactive protein, is expressed in response to inflammatory stimuli by endothelial cells, macrophages, and monocytes. Recent studies suggest that PTX3 levels in early pregnancy are associated with the subsequent development of early onset PE, but not fetal growth restriction. Poon et al. have recently reported that a combination of PTX3 and PIGF with other information, such as maternal health history, biophysical markers like mid-arterial pressure and Doppler ultrasound measurements, performs better for PE prediction in patients at 11 to 13 weeks pregnancy. Table 1 summarizes potential biomarkers in maternal blood for the prediction (first trimester and second trimester) or detection of PE.

**Combined screening**

As described, no single marker tested thus far has sufficient clinical value in the prediction of PE. Instead, the value of biomarkers seems to be in increasing the predictive value of panels of tests, which include other clinical measurements. Different pathophysiological pathways are thought to converge in the common clinical syndrome of PE. This etiological complexity almost precludes the notion that a single test could not be successfully used to predict PE. The search continues to find a combination of tests that will work better than, or in association with, uterine artery Doppler to maintain the high sensitivity, but to improve specificity.
many originating from the Fetal Medicine Foundation (FMF, London). Table 2 summarizes the detection rate for multiple markers of PE in the first trimester.

One particularly promising predictive model for the first trimester has recently been published by Poon et al. The authors evaluated 7,797 women with singleton, first-trimester pregnancies attending clinics for routine care, with a 2% overall incidence of PE. The predictive model incorporated maternal factors, uterine artery Doppler, maternal MAP, PAPP-A, and PlGF. For a 5% false-positive rate, the sensitivity and specificity for early-onset PE were 93 and 94%, respectively. The likelihood ratio for a positive test was 16.5 and the negative was 0.06, easily meeting the World Health Organization (WHO) criteria for a screening test. As observed in other studies, the predictive results for late-onset PE and gestational hypertension were lower at 36 and 18%, respectively. Overall, one in five women who screened as positive with the combined tests went on to develop a hypertensive disease of pregnancy. The editorial accompanying the article points out that these results need to be tested by other investigators and in different populations before we can be certain that this model for combined tests can be universally applied. These results, however, are extremely promising, and the component tests of the model could, at least in the developed world, be easily measured in most settings.

### Table 1. Summary of potential biomarkers for the prediction or detection of PE in maternal peripheral blood (adapted from Grill et al. (42))

<table>
<thead>
<tr>
<th>Biomarker</th>
<th>1st trimester</th>
<th>2nd trimester</th>
<th>Manifested PE</th>
<th>Reported combinations for prediction</th>
<th>Altered levels correlated with</th>
</tr>
</thead>
<tbody>
<tr>
<td>PAPP-A</td>
<td>↑</td>
<td>↓</td>
<td>↑</td>
<td>Ultrasound</td>
<td>Birth-weight, IUGR</td>
</tr>
<tr>
<td>PP-13</td>
<td>↑</td>
<td>↑</td>
<td>↑</td>
<td></td>
<td>Preterm delivery</td>
</tr>
<tr>
<td>Cell-free fetal DNA</td>
<td>↑</td>
<td>↑</td>
<td>↑</td>
<td></td>
<td>IUGR</td>
</tr>
<tr>
<td>MAP</td>
<td>↑</td>
<td>↑</td>
<td>↑</td>
<td>PAPP-A</td>
<td>IUGR</td>
</tr>
<tr>
<td>uA-PI</td>
<td>↑</td>
<td>↑</td>
<td>↑</td>
<td>PlGF</td>
<td>Polyhydraminosis, Trisomy 21,</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>Trisomy 18, Preterm lab</td>
</tr>
<tr>
<td>sflt-1</td>
<td></td>
<td></td>
<td>↑</td>
<td></td>
<td></td>
</tr>
<tr>
<td>sEng</td>
<td></td>
<td></td>
<td>↑</td>
<td></td>
<td></td>
</tr>
<tr>
<td>P-selectin</td>
<td>↑</td>
<td>↑</td>
<td>↑</td>
<td></td>
<td></td>
</tr>
<tr>
<td>PTX3</td>
<td>↑</td>
<td>↑</td>
<td>↑</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

### Table 2. First trimester multiparametric model detection rates for early-onset PE

<table>
<thead>
<tr>
<th>DR at 5% FPR</th>
<th>History</th>
<th>MAP</th>
<th>uA-PI</th>
<th>PAPP-A</th>
<th>PlGF</th>
<th>Reference</th>
</tr>
</thead>
<tbody>
<tr>
<td>33</td>
<td>X</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>Yu et al.44</td>
</tr>
<tr>
<td>38</td>
<td>X</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>Akolekar et al.57</td>
</tr>
<tr>
<td>47</td>
<td>X</td>
<td>X</td>
<td></td>
<td></td>
<td></td>
<td>Poon et al.25</td>
</tr>
<tr>
<td>54</td>
<td>X</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>Akolekar et al.57</td>
</tr>
<tr>
<td>60</td>
<td>X</td>
<td>X</td>
<td>X</td>
<td></td>
<td></td>
<td>Foidart et al.40</td>
</tr>
<tr>
<td>78</td>
<td>X</td>
<td>X</td>
<td>X</td>
<td>X</td>
<td></td>
<td>Akolekar et al.57</td>
</tr>
<tr>
<td>78</td>
<td>X</td>
<td>X</td>
<td>X</td>
<td>X</td>
<td></td>
<td>Foidart et al.40</td>
</tr>
<tr>
<td>84</td>
<td>X</td>
<td>X</td>
<td>X</td>
<td>X</td>
<td></td>
<td>Poon et al.49</td>
</tr>
<tr>
<td>89</td>
<td>X</td>
<td>X</td>
<td>X</td>
<td>X</td>
<td></td>
<td>Poon et al.25</td>
</tr>
<tr>
<td>93</td>
<td>X</td>
<td>X</td>
<td>X</td>
<td>X</td>
<td></td>
<td>Poon et al.73</td>
</tr>
</tbody>
</table>

**Perspectives for prevention**

Many therapeutic interventions have been trialled, but the pattern of outcomes is similar. Initial small trials often show promising results followed by disappointing outcomes in larger studies. Currently, no definitive treatment or effective prophylaxis for PE is in widespread clinical use. Delivery and consequent removal of the placenta is the “treatment”, often with a premature baby as the result. Close surveillance of mother and fetus is necessary for the timing of delivery in order to reduce morbidity and mortality rates.

To date, only aspirin and calcium showed some benefits in terms of prevention. A recent meta-analysis of individualised patient data from 31 randomised trials involving 32,217 women, revealed that aspirin showed a significant 10% reduction in the incidence of PE (relative risk of 0.9, 95%CI=0.84-0.97)54. Similar reductions in delivery before 34 weeks (RR=0.90; 0.83-0.98) and a serious adverse outcome (RR=0.9; 0.85-0.96) were seen. The findings broadly supported those of the preceding Cochrane review21.

In 2009, Bujold et al. published a meta-analysis that assessed the influence of gestational age at the time...
of starting the aspirin treatment, on the incidence of PE in women at increased risk on the basis of abnormal uterine artery Doppler. They found a 52% reduction in the risk of PE compared with the Control Group, when aspirin treatment was started before 16 weeks of pregnancy. When aspirin was started after 16 weeks, there was no significant reduction in PE risk.

The Cochrane review of trials found that calcium supplementation during pregnancy is a safe and relatively cost-effective means of reducing the risk of high blood pressure in women with increased risk, and women with low dietary calcium. No adverse effects were found, but further research is needed to find the ideal dosage for supplementation and to confirm the results that stem from several rather small trials. A large, multicenter trial performed between 1992 and 1995 (CPEP) did not find a risk reduction in healthy, nulliparous women. A more recent study showed that calcium supplementation did not prevent PE, but it reduced its severity and maternal and neonatal morbidity.

### Referências


### Conclusion

It is now increasingly accepted that PE is better defined as a syndrome rather than a single disorder. Early-onset PE is strongly associated with deficient trophoblast invasion and failure of normal spiral artery remodeling. Late-onset PE may be caused by increased maternal vascular susceptibility to the normal inflammatory state of pregnancy or atherosclerosis of a placenta that was initially normally developed. The most promising predictive models incorporate panels of tests evaluating different aspects of maternal susceptibility and placentation, such as maternal risk factors, mean arterial blood pressure, uterine artery Doppler, and biomarkers. There is sufficient data on some combinations of markers to make reasonable estimates of PE risk. Prospective studies are necessary to evaluate risk prediction in different populations. Furthermore, we need to evaluate the potential of novel biomarkers, generated by novel research strategies, in order to try to improve the predictive performance of the existing models.


Early screening for preeclampsia


